Phase II study designed to evaluate the safety and efficacy of BIIB057 in Subjects with Rheumatoid Arthritis who have experienced an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARDs).
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01652937?cond=%22Arthritis%22&lup_s=08/23/2013&lup_d=30
